- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
LSD1 Antibody / Epigenetic Regulation Marker [clone PCRP-KDM1A-1A10] (V4694)
Email: info@nsjbio.com
| Catalog No | Formulation | Size | Price (USD) | ||
|---|---|---|---|---|---|
|
V4694-100UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide | 100 ug | 559 | |
|
|
V4694-20UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide | 20 ug | 259 | |
|
|
V4694SAF-100UG | 1 mg/ml in 1X PBS; BSA free, sodium azide free | 100 ug | 559 |
| Availability | 1-3 business days |
| Species Reactivity | Human |
| Format | Purified |
| Host | Mouse |
| Clonality | Monoclonal (mouse origin) |
| Isotype | Mouse IgG2a |
| Clone Name | PCRP-KDM1A-1A10 |
| Purity | Protein A/G affinity |
| UniProt | O60341 |
| Localization | Nucleus |
| Applications | Flow Cytometry : 1-2ug/million cells Western Blot : 1-2ug/ml Immunohistochemistry (FFPE) : 1-2ug/ml for 30 min at RT |
| Limitations | This LSD1 Antibody / Epigenetic Regulation Marker is available for research use only. |
|
Review this product on BioCompare and get a $20 Amazon gift card
|
Related Products
|
Lysine-specific demethylase 1 (KDM1A), commonly known as LSD1, is an epigenetic regulatory protein involved in chromatin remodeling, transcriptional repression, and histone modification pathways. LSD1 Antibody / Epigenetic Regulation Marker is suitable for studies involving chromatin-associated regulatory proteins, transcriptional control mechanisms, stem cell signaling, and cancer epigenetics. LSD1 belongs to the flavin adenine dinucleotide-dependent amine oxidase family and functions as a histone demethylase capable of modulating transcription-associated chromatin states through removal of methyl groups from histone substrates.
LSD1 antibody, also referred to as KDM1A antibody, Lysine-specific demethylase 1 antibody, Histone lysine demethylase antibody, and BHC110 antibody in the literature, recognizes a nuclear regulatory protein that participates in transcriptional repression and activation complexes associated with chromatin remodeling pathways. LSD1 was one of the first histone demethylases identified and remains a central regulator of epigenetic signaling networks controlling cellular differentiation, stem cell maintenance, and adaptive transcriptional responses. The protein functions within multiprotein chromatin remodeling complexes including CoREST-associated transcriptional repression assemblies that regulate accessibility of DNA-associated regulatory regions.
Epigenetic regulatory proteins such as LSD1 are critical for coordinated control of lineage specification, developmental signaling, and cellular identity. LSD1 contributes to regulation of histone H3 lysine methylation states associated with transcriptional activation and repression pathways. Through modulation of chromatin architecture and transcription factor accessibility, LSD1 influences pathways controlling proliferation, differentiation, epithelial-mesenchymal transition, and cellular plasticity. The protein is predominantly localized within the nucleus, consistent with its role in chromatin-associated transcriptional regulation.
Dysregulated LSD1 expression has been linked to numerous malignancies including acute myeloid leukemia, prostate cancer, breast cancer, neuroblastoma, and small cell lung cancer. Because epigenetic remodeling pathways influence tumor progression, stemness, and therapeutic resistance, LSD1 has emerged as a major target in cancer epigenetics and drug development research. LSD1 inhibitors are under active investigation for treatment strategies involving transcriptional reprogramming and differentiation-associated therapies.
Immunohistochemistry and immunofluorescence analyses support the expected nuclear localization pattern of LSD1/KDM1A in human cells and tissues, consistent with the intracellular distribution expected for a chromatin-associated epigenetic regulator. HuProt(TM) protein microarray specificity validation further supports selective recognition of LSD1 among more than 19,000 full-length human proteins. The combination of IHC, IF, and protein microarray validation supports use of this antibody for studies involving epigenetic signaling, chromatin remodeling, transcriptional repression, and cancer-associated regulatory pathways.
An antibody targeting LSD1 can therefore support investigations involving histone demethylation pathways, epigenetic transcriptional regulation, chromatin remodeling complexes, stem cell-associated signaling networks, and cancer-related transcriptional reprogramming mechanisms.
LSD1/KDM1A functions as a chromatin-associated histone demethylase involved in epigenetic transcriptional regulation; explore related chromatin remodeling and histone modification targets on our Epigenetics Antibodies landing page.
Optimal dilution of the LSD1 Antibody / Epigenetic Regulation Marker should be determined by the researcher.
A recombinant partial protein sequence (within amino acids 152-279) from the human protein was used as the immunogen for the LSD1 Antibody.
Aliquot the LSD1 Antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
LSD1 antibody, KDM1A antibody, Lysine-specific demethylase 1 antibody, Histone lysine demethylase antibody, BHC110 antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.
Powered by Bioz
